CME Information
Overview
Provider Statement
This continuing medical education activity is provided by 
Support Statement
This activity is supported by an educational grant from Merck & Co., Inc.
Target Audience
The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with non-small cell lung cancer.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Outline clinical evidence regarding long-term outcomes of available immune checkpoint inhibitors and combinations in patients with advanced NSCLC lacking targetable molecular aberrations.
- Identify treatment options for patients with advanced NSCLC lacking oncogenic driver aberrations based on available long-term evidence, PD-L1 levels, safety considerations, and patient preferences.
- Evaluate the latest data regarding emerging combinations for first-line therapy of advanced NSCLC lacking targetable driver alterations.
- Discuss the potential roles for emerging combinations in the treatment of progressive disease based on mechanisms of action and available clinical data.
Activity Co-Chairs
Justin Gainor, MD
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Associate Professor
Harvard Medical School
Boston, MA
Rachel E. Sanborn, MD
Medical Director, Thoracic Oncology Program
Medical Director, Phase I Clinical Trials Program
Earle A. Chiles Research Institute
Providence Cancer Institute
Portland, OR
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, September 30, 2022, to September 29, 2023.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Activity Co-Chairs report the following relationship(s)
Justin Gainor, MD
Consultant: AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Gilead, Merck, Novartis, Pfizer, Regeneron
Independent Research Contractor: ALX Oncology, Array BioPharma, Genentech, Jounce, Merck, Novartis, Tesaro
Rachel E. Sanborn, MD
Advisor: AstraZeneca, GlaxoSmithKline
Consultant: Daiichi Sankyo, EMD Serono, MacroGenics, Regeneron, Sanofi
Speaker Contracted by Ineligible Company: AstraZeneca
Independent Research Contractor: AstraZeneca, Bristol Myers Squibb, Merck
Reviewer reports the following relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com